Clinical Utility of Drug-Eluting Beads Bronchial Arterial Chemoembolization in Advanced Refractory Non-Small Cell Lung Cancer.
- 1Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Abstract
Objective: This study mainly focused on evaluating the efficacy and safety of drug-eluting beads bronchial arterial chemoembolization (DEB-BACE) in treating advanced refractory non-small cell lung cancer (NSCLC) patients, with an exploratory investigation of whether combining DEB-BACE with anlotinib could bring additional benefits and identification of key prognostic factors. Methods: A retrospective analysis was conducted on 104 eligible patients, including 64 who received DEB-BACE monotherapy and 40 who received DEB-BACE combined with anlotinib. Kaplan-Meier method, log-rank test, and Cox proportional hazard model were used for survival and prognostic analyses. Primary endpoints were progression-free survival (PFS) and overall survival (OS); secondary endpoints included objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). Results: The entire cohort had a median PFS of 13.9 months and median OS of 17.0 months, suggesting a potential survival benefit of DEB-BACE in advanced NSCLC. As an exploratory analysis, the combination group showed numerical advantages in PFS (13.9 vs. 10.6 months), OS (20.3 vs. 14.0 months), and ORR, without significant differences (all p > 0.05). ECOG 2 was an independent poor prognostic factor for PFS (HR = 2.602, p = 0.020) and tended to affect OS (HR = 2.259, p = 0.050). No grade 4 AEs or treatment-related deaths occurred; the 5.8% grade 3 AEs were all manageable. Conclusions: DEB-BACE may be effective and safe as a treatment option for advanced NSCLC patients, although prospective controlled studies are needed to confirm these findings. The combination of DEB-BACE with anlotinib, as an exploratory strategy, shows numerical benefits but no significant superiority.
Related
- Retrospective observational study of transcatheter arterial chemoembolization (TACE) combined with PD-1 inhibitor and tyrosine kinase inhibitor (TKI) in advanced hepatocellular carcinoma.
- Clinical efficacy of transcatheter arterial chemoembolization combined with surgical resection for treating spontaneous rupture of hepatocellular carcinoma
- Drug-eluting bead transarterial chemoembolization with immunotherapy and targeted therapy for advanced clear cell renal cell carcinoma: A case report.
- Primary bronchial fibrous histiocytoma mimicking refractory asthma in a child: A fatal case of misdiagnosis and airway obstruction.
- Complete transcatheter closure of residual aortopulmonary window in an elderly patient allowing optimization of refractory pulmonary arterial hypertension therapy.
BibTeX
@article{li2026clinical,
title = {{Clinical Utility of Drug-Eluting Beads Bronchial Arterial Chemoembolization in Advanced Refractory Non-Small Cell Lung Cancer.}},
author = {Yawei Li and Junqing Xi and Yuxi Liu and Xiao Li and Xiaowu Zhang},
journal = {Current oncology (Toronto, Ont.)},
year = {2026},
month = oct,
doi = {10.3390/curroncol33100600},
url = {https://europepmc.org/article/MED/42930167},
note = {CC BY},
}
RIS
TY - JOUR
TI - Clinical Utility of Drug-Eluting Beads Bronchial Arterial Chemoembolization in Advanced Refractory Non-Small Cell Lung Cancer.
AU - Yawei Li
AU - Junqing Xi
AU - Yuxi Liu
AU - Xiao Li
AU - Xiaowu Zhang
PY - 2026
DA - 2026/10/05
JO - Current oncology (Toronto, Ont.)
DO - 10.3390/curroncol33100600
UR - https://europepmc.org/article/MED/42930167
AB - Objective: This study mainly focused on evaluating the efficacy and safety of drug-eluting beads bronchial arterial chemoembolization (DEB-BACE) in treating advanced refractory non-small cell lung cancer (NSCLC) patients, with an exploratory investigation of whether combining DEB-BACE with anlotinib could bring additional benefits and identification of key prognostic factors. Methods: A retrospective analysis was conducted on 104 eligible patients, including 64 who received DEB-BACE monotherapy and 40 who received DEB-BACE combined with anlotinib. Kaplan-Meier method, log-rank test, and Cox proportional hazard model were used for survival and prognostic analyses. Primary endpoints were progression-free survival (PFS) and overall survival (OS); secondary endpoints included objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). Results: The entire cohort had a median PFS of 13.9 months and median OS of 17.0 months, suggesting a potential survival benefit of DEB-BACE in advanced NSCLC. As an exploratory analysis, the combination group showed numerical advantages in PFS (13.9 vs. 10.6 months), OS (20.3 vs. 14.0 months), and ORR, without significant differences (all p > 0.05). ECOG 2 was an independent poor prognostic factor for PFS (HR = 2.602, p = 0.020) and tended to affect OS (HR = 2.259, p = 0.050). No grade 4 AEs or treatment-related deaths occurred; the 5.8% grade 3 AEs were all manageable. Conclusions: DEB-BACE may be effective and safe as a treatment option for advanced NSCLC patients, although prospective controlled studies are needed to confirm these findings. The combination of DEB-BACE with anlotinib, as an exploratory strategy, shows numerical benefits but no significant superiority.
SN - 1198-0052
SN - 1718-7729
ER -